Quantcast

Latest Diabetic retinopathy Stories

2011-03-24 15:30:00

SOUTH PORTLAND, Maine, March 24, 2011 /PRNewswire/ -- Anthem Blue Cross and Blue Shield in Maine is now offering Blue View Vision(SM), an affordable and flexible vision plan that provides access to more than 125 network providers across the state, and more than 50,000 providers and provider locations nationwide. The Blue View Vision(SM) network includes ophthalmologists, optometrists, and opticians. In addition to private practitioners, Blue View Vision(SM)'s broad national network...

2011-03-22 14:18:00

LOUISVILLE, Ky. March 22, 2011 /PRNewswire/ -- Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people - including children - in the United States. Approximately one-quarter of those people do not know they're living with the disease. "Many people are at risk of developing type 2 diabetes, which can have serious effects on a person's eyesight," said Dr....

2011-03-22 14:07:00

NASHVILLE, March 22, 2011 /PRNewswire/ -- Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people - including children - in the United States. Approximately one-quarter of those people do not know they're living with the disease. "Many people are at risk of developing type 2 diabetes, which can have serious effects on a person's eyesight," said Dr. Mark...

2011-03-21 03:09:00

LONDON, March 21, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology...

2011-03-18 17:12:00

FREMONT, Calif., March 18, 2011 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655...

2011-03-11 08:33:00

NORTH HAVEN, Conn., March 11, 2011 /PRNewswire/ -- Anthem Blue Cross and Blue Shield in Connecticut is now offering Blue View Vision, an affordable and flexible vision plan that provides access to more than 700 network providers in Connecticut, and more than 50,000 providers and provider locations nationwide. The Blue View Vision network includes ophthalmologists, optometrists, and opticians. In addition to private practitioners, Blue View Vision provides network access to retailers with...

2011-02-22 07:00:00

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months. Regeneron's submission includes a...

2011-02-17 21:40:27

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes. In a study using diabetic rats, lead author Azza El-Remessy, assistant professor in the University of Georgia College of Pharmacy, and her colleagues found that statins prevent free radicals in the retina from killing nerves important to maintaining vision. The results of the study are published in the March edition of the journal...

2011-02-15 08:20:43

(Ivanhoe Newswire) -- Grab some walnuts and a plate of fish, new research shows Omega-3 fatty acids found in these foods may keep you seeing straight. Past research has shown that Omega 3's may help prevent human blindness, but a new study in mice reveals exactly how that works. Omega-3 fatty acids are fats commonly found in fish oil.  Several years ago researchers at Children's Hospital Boston determined that the fatty acids helped to prevent retinopathy, which is a major form of...

2011-02-10 00:27:28

Study reveals how they work in preventing several forms of blindness Omega-3 fatty acids "“fats commonly found in fish oil "“ were shown several years ago to prevent retinopathy, a major form of blindness, in a mouse model of the disease. A follow-up study, from the same research team at Children's Hospital Boston, now reveals exactly how omega-3's provide protection, and provides reassurance that widely used COX-inhibiting drugs like aspirin and NSAIDs don't negate their benefit....


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'